{"denoms":[{"counts":[{"groupId":"BG000","value":"10"}],"units":"Participants"}],"groups":[{"description":"Bortezomib 1.3 milligram (mg) per meter\\^2 (m\\^2) bolus (a large amount) intravenous (into the vein) injection will be administered once daily on Days 1, 4, 8 and 11 of each 21-day cycle with addition of Dexamethasone 20 mg per day administered orally, once daily on Days 1 and 2, Days 4 and 5, Days 8 and 9 and Days 11 and 12 of each 21-day cycle as per Investigator's discretion for those participants who experience disease progression after treatment completion up to Cycle 2 or have no change from Baseline after completion of at least 4 cycles. The treatment will be given up to 8 cycles (24 weeks).","id":"BG000","title":"Bortezomib and Dexamethasone"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"< 65"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Between 65-69"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"Between 70-74"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":">=75"}],"paramType":"NUMBER","title":"Age, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}]}